Novo Nordisk is actively monitoring and taking action (including but not limited to issuing cease-and-desist letters) against those entities that are engaging in the unlawful sale of compounded semaglutide, disseminating false advertising, and infringing its trademarks. Scott Brunner, CEO of the Alliance for Pharmacy Compounding (A4PC), says that, based on reports from some compounding pharmacies, compounding pharmacies have been able to access semaglutide from legitimate FDA-registered facilities
[3] [4] Tirzepatide may decrease the effectiveness of oral contraceptives and is not recommended during pregnancy due to weight loss effects
If you're not sure how to adjust your routine around the medicine, message us
Quattro Advisors LLC acquired a new stake in Quest Diagnostics in the fourth quarter valued at $25,000
10.1161/CIRCRESAHA.113.301086 16
Give us a call at 804-717-5000 or fill out our interest form